Dr. Peters Discusses the FLAURA Trial for EGFR-Mutated NSCLC

Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non—small cell lung cancer (NSCLC).

The FLAURA trial is investigating osimertinib (Tagrisso) versus standard of care in the frontline setting. The primary endpoint of this study is progression-free survival (PFS). The FLAURA trial has shown an improvement of PFS with 18.6 months.

It has also been discovered the osimertinib is a good regimen for CNS metastases, states Peters. Additionally, there was a beneficial toxicity profile for the patients who received osimertinib. According to Peters, osimertinib is the new standard of care for patient with EGFR-mutated NSCLC.